Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis

Overview of attention for article published in Cochrane database of systematic reviews, August 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 16 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 44 Dimensions

Readers on

mendeley: 222 Mendeley

Summary X Facebook Dimensions citations

So far, Dimensions has found 44 publications that cite this research output.

44

The most recent citing publications are shown below. View all 44 publications that cite this research output on Dimensions.

Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis

Article in Frontiers in Pharmacology (December 2023)

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)

Article in Cochrane Database of Systematic Reviews (November 2023)

Targeted Therapy for Cystic Fibrosis in Children

Article in Innovative medicine of Kuban (November 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.